ApprovalTrail

Approval · Notice of Compliance 23619 · 2020

FULPHILA: Notice of Compliance 23619

Issued May 15, 2020

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
23619
Date
May 15, 2020
Company
BGP Pharma ULCEtobicoke, Ontario, Canada
Product type
Biologic
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
Additional manufacturing site and manufacturing scale up
Canadian reference product
NEULASTA

Products in this notice

BrandDINStatus today
FULPHILANot yet assigned—

Medicinal ingredients